Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.

WM, Stadler; RA, Figlin; DF, McDermott; JP, Dutcher; JJ, Knox; WH Jr, Miller; JD, Hainsworth; CA, Henderson; JR, George; J, Hajdenberg; TL, Kindwall-Keller; MS, Ernstoff; HA, Drabkin; BD, Curti; L, Chu; CW, Ryan; SJ, Hotte; C, Xia; L, Cupit; RM, Bukowski

doi:10.1002/cncr.24864

Public

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.

Shared by NobleBlocks on Mar 1, 2010 • 12:00 AM UTC

Authors:

Stadler WM

Figlin RA

McDermott DF

Abstract

<h4>Background</h4>The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval.<h4>Methods</h4>In this nonrandomized, open-label expanded access program, 2504 patients from the United States and ...

Discussions